文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

阿替利珠单抗联合立体定向放疗治疗转移性、复发性或持续性宫颈癌:II期多中心研究结果

Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-05-14

这项前瞻性II期多中心试验纳入21例转移性、复发性或持续性宫颈癌患者,接受SBRT后序贯阿替利珠单抗1200 mg每3周静脉给药。未照射靶病灶客观缓解率为38%(8例),达到研究预设终点;PD-L1阴性肿瘤中亦观察到缓解,联合治疗耐受性良好。

要点

  • 未照射靶病灶客观缓解率38%,达到研究预设终点。
  • PD-L1阴性肿瘤中亦观察到缓解。
  • 常见≥2级毒性为淋巴细胞减少、恶心呕吐、低钠血症。

核心结论

  • SBRT联合阿替利珠单抗在未筛选PD-L1的转移性宫颈癌中耐受性良好,PD-L1阴性肿瘤亦出现缓解。

研究设计与样本

  • 前瞻性II期多中心试验,纳入21例转移性、复发性或持续性宫颈癌患者,至少2个可测量病灶。
  • 治疗方案为SBRT后序贯阿替利珠单抗1200 mg静脉给药每3周一次。
  • 主要终点为未照射靶病灶的客观缓解率。

主要发现

  • 中位随访23.6个月,腺癌10例(48%),PD-L1阴性15例(71%)。
  • 最佳总体疗效:部分缓解5例(24%),疾病稳定12例(57%)。
  • 中位缓解持续时间8.6个月(95% CI,4.5-13.6个月)。
  • 未照射靶病灶客观缓解8例(38%),达到研究预设终点。
  • 至少可能归因于研究治疗的≥2级毒性:淋巴细胞减少6例(29%)、恶心呕吐3例(14%)、低钠血症3例(14%)。

临床怎么用

  • 对于转移性、复发性或持续性宫颈癌患者,SBRT联合阿替利珠单抗可作为耐受性良好的治疗选择。
  • PD-L1阴性患者也可能从该联合治疗中获益,不应仅凭PD-L1状态排除免疫治疗。

局限性

  • 样本量较小(21例),随访时间有限(中位23.6个月)。
  • 单臂设计,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab is approved for PD-L1+ but not PD-L1 negative metastatic, recurrent, or persistent cervical cancer. Response rates to single agent anti-PD-1/PD-L1 therapy have been modest with no responses noted in PD-L1 negative tumors. METHODS AND MATERIALS: The study is designed as a prospective, phase II multi-institutional trial of stereotactic body radiation therapy (SBRT) followed by atezolizumab (1200 mg intravenously q3 weeks). Key eligibility criteria included patients with metastatic, recurrent, or persistent cervical cancer with at least 2 distinct lesions. The primary objective was objective response rate measured at the unirradiated target lesion. RESULTS: A total of 21 patients were enrolled. Median follow-up is 23.6 months. The majority of patients had adenocarcinoma (n = 10; 48%) and were PD-L1 negative (n = 15; 71%). The best overall response was a partial response in 5 (24%) and stable disease in 12 (57%) patients. The median duration of response was 8.6 months (95% CI, 4.5-13.6 months). An objective response at the unirradiated target lesion was observed in 8 patients (38%), meeting the study defined endpoint. Responses were noted in PD-L1 negative tumors. The most common grade ≥2 toxicities at least possibly attributed to study therapy included lymphopenia (n = 6; 29%), nausea/vomiting (n = 3; 14%), and hyponatremia (n = 3; 14%). CONCLUSIONS: In this first trial of SBRT and atezolizumab in metastatic cervical cancer unselected for PD-L1, combination therapy was well tolerated. Responses were noted in PD-L1 negative tumors. Combination therapy may allow for improved response rates to immune checkpoint inhibition in metastatic cervical cancer particularly in PD-L1 negative tumors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ahmed KA, Quick AM, Chon HS, et al. Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 40379142. doi:10.1016/j.ijrobp.2025.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。